<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614560</url>
  </required_header>
  <id_info>
    <org_study_id>SGN33A-003</org_study_id>
    <nct_id>NCT02614560</nct_id>
  </id_info>
  <brief_title>A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients</brief_title>
  <official_title>A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab
      talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine
      in sequence with standard treatments before a planned stem cell transplant, or as maintenance
      therapy after a stem cell transplant. The main purpose of the study is to find the best dose
      and determine the anti-leukemic activity of vadastuximab talirine, given either pre- or
      post-allogeneic stem cell transplant (alloSCT) for adults with relapsed or refractory AML.
      This will be determined by assessing the safety and tolerability of vadastuximab talirine. In
      addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will
      be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 10, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through approximately 49 days following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 49 days following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>12 months after the alloSCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of MRD negativity</measure>
    <time_frame>Through 30 days following alloSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>Up to 3 months following allo SCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Pre-allo (before stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-allo (after stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-allo vadastuximab talirine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)</description>
    <arm_group_label>Pre-allo (before stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 140 mg/m2 intravenously, 2 days before the transplant</description>
    <arm_group_label>Pre-allo (before stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadastuximab talirine</intervention_name>
    <description>Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant</description>
    <arm_group_label>Pre-allo (before stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadastuximab talirine</intervention_name>
    <description>Post-allo (after stem cell transplant) given on Day 1 of each cycle</description>
    <arm_group_label>Post-allo (after stem cell transplant)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed/refractory acute myeloid leukemia (AML) except for acute promyelocytic
             leukemia

          -  Eastern Cooperative Oncology Group status of 0 or 1

          -  Adequate baseline renal and hepatic function

          -  For Pre-allo Part A (before stem cell transplant): Relapsed or refractory AML (greater
             than 5% blasts)

          -  For Pre-allo Part A (before stem cell transplant): Availability of an HLA matched
             related or unrelated donor

          -  For Pre-allo Part A (before stem cell transplant): Eligible for an allogeneic
             hematopoietic stem cell transplant

          -  For Post-allo Part B: Transplant must have been performed with active AML (greater
             than 5% blasts) using a conventional conditioning regimen and have achieved CR or CRi
             post-alloSCT (with ANC greater than or equal to 1,000 and platelet greater than or
             equal to 50,000)

          -  For Post-allo Part B: Treatment must begin at least 60 days, but no more than 100 days
             post-transplant.

        Exclusion Criteria:

          -  Inadequate heart function

          -  Inadequate lung function

          -  Previous central nervous system leukemia

          -  Any history of another metastatic malignancy

          -  Anti-leukemia treatment within14 days of study drug (other than hydroxyurea or
             6-mercaptopurine), immunosuppressive therapy (except for GVHD treatment/prophylaxis in
             Part B), or investigational agents

          -  For Pre-allo Part A (before stem cell transplant): Partially matched donors (related
             or unrelated) and umbilical cord blood cells are excluded as the source of
             hematopoietic stem cells

          -  For Pre-allo Part A (before stem cell transplant): Prior alloSCT

          -  For Post-allo Part B: Active GVHD Grade 2 or higher

          -  For Post-allo Part B:History of veno-occlusive disease requiring defibrotide

          -  For Post-allo Part B: History of Grade 2 or higher hepatic GVHD

          -  For Post-allo Part B: Concurrent use of corticosteroids equivalent of prednisone at a
             dose of greater than 0.5 mg/kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Garfin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>United States</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <disposition_first_submitted>January 3, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 3, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 5, 2018</disposition_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>antibody-drug conjugate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

